BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
15 nov. 2020 19h35 HE
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Groundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory Disease
01 oct. 2020 08h30 HE
|
180 Life Sciences Corp.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. (NASDAQ: KBLM) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03 sept. 2020 21h42 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Therapeutic Antibody Pioneers Professor Sir Marc Feldmann and Dr. H. Michael Shepard Formally Launch Enosi Life Sciences
02 sept. 2020 09h00 HE
|
Enosi Life Sciences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences...
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
17 août 2020 10h57 HE
|
BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
05 août 2020 18h16 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
15 juil. 2020 13h34 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
02 juil. 2020 11h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
23 juin 2020 17h21 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
21 mai 2020 13h58 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...